Therapeutic Drug Monitoring and Clinical Applications
Therapeutic drug monitoring (TDM) is the applied branch of clinical pharmacokinetics in which measured drug concentrations are used, together with pharmacokinetic reasoning, to interpret and individualise drug exposure. It is most useful for drugs with a narrow margin between effective and toxic concentrations, large between-patient variability, and a concentration that predicts effect better than the dose does.
Definition
Therapeutic drug monitoring is the measurement of drug (or metabolite) concentrations in biological fluids, interpreted in the light of pharmacokinetic and pharmacodynamic relationships, to support individualised dose adjustment toward a defined target exposure.
Scope
This area orients the reader to why and when drug concentrations are measured and how pharmacokinetic principles connect a dose to a concentration and a concentration to an effect. It introduces the target-concentration idea, the sources of variability that make a fixed dose unreliable, and the logic of loading and maintenance dosing. Detailed treatment of each strand is delegated to the child topics. It is a reference overview of methodology, not clinical dosing guidance.
Sub-topics
Core questions
- For which drugs does measuring a concentration add information beyond observing the dose and the clinical response?
- How do pharmacokinetic parameters (clearance, volume of distribution, half-life) link a dosing regimen to the concentrations a patient experiences?
- What target concentration or exposure index best predicts efficacy and toxicity for a given drug?
- How should sampling time relative to the dose be chosen so that a measured concentration is interpretable?
Key concepts
- Target concentration and therapeutic range
- Clearance, volume of distribution, and half-life
- Steady state and time to steady state
- Trough, peak, and area-under-the-curve sampling
- Between-patient and within-patient variability
- Loading versus maintenance dosing
- Candidate drugs for TDM (narrow index, variable kinetics, concentration-effect link)
Key theories
- Pharmacokinetic-pharmacodynamic (PK-PD) linkage
- Effect is modelled as a function of concentration rather than of dose, with pharmacokinetics describing how the body produces the concentration-time profile and pharmacodynamics describing how that profile produces effect; this linkage is the conceptual basis for using a measured concentration to guide dosing.
Mechanisms
A dosing regimen interacts with a patient's clearance and volume of distribution to generate a concentration-time profile; pharmacodynamics then maps that profile to effect. When variability in these parameters is large and the concentration predicts effect better than the dose, a measured concentration carries information that the regimen alone does not. TDM closes this loop: a sample taken at a defined time is compared with a target exposure, and the regimen is reconsidered to move the patient's profile toward that target. The same pharmacokinetic relationships explain why a loading dose fills the volume of distribution quickly while the maintenance rate must match clearance to hold steady state.
Clinical relevance
TDM underpins the rational use of several drug classes for which fixed dosing is unreliable, and understanding it is part of interpreting pharmacology and laboratory data in the health sciences. This entry describes the methodology by which exposure is individualised and the evidence about its value; it is educational reference material and not a source of dosing recommendations for any individual patient.
Evidence & guidelines
Systematic appraisal has found that the clinical and economic value of TDM is well supported for some drugs and weaker for others, so its use is drug-specific rather than universal (Touw et al., 2005). The foundational PK-PD framework that justifies concentration-guided dosing was articulated by Holford and Sheiner (1981), and standard texts such as Rowland and Tozer (2011) codify the underlying pharmacokinetic concepts.
History
Routine concentration measurement became feasible as immunoassays and chromatographic methods spread through clinical laboratories in the 1960s and 1970s, coinciding with the maturation of clinical pharmacokinetics as a discipline. Holford and Sheiner's 1981 synthesis of pharmacokinetic-pharmacodynamic modelling gave the practice a quantitative rationale, and subsequent decades refined which drugs benefit and which exposure indices to target.
Debates
- Which drugs genuinely benefit from routine monitoring?
- Evidence for clinical and cost benefit is strong for some agents and limited for others, so blanket monitoring is not justified; selecting drugs by narrow therapeutic index, kinetic variability, and a clear concentration-effect relationship remains a matter of judgement informed by evidence.
Key figures
- Lewis Sheiner
- Nicholas Holford
- Malcolm Rowland
- Thomas Tozer
Related topics
Seminal works
- holford-sheiner-1981
- touw-2005
- wilkinson-2005
Frequently asked questions
- Does every drug need therapeutic drug monitoring?
- No. Monitoring adds information mainly for drugs with a narrow therapeutic window, large unpredictable variability in handling, and a concentration that predicts effect better than the dose; for most drugs the clinical response and the dose are sufficient guides.
- What is the difference between TDM and pharmacokinetics in general?
- Pharmacokinetics is the science describing how the body handles drugs; therapeutic drug monitoring is its applied use at the bedside, where measured concentrations are interpreted through pharmacokinetic principles to individualise exposure.